HTA di Denosumab nella prevenzione delle fratture da osteoporosi

Translated title of the contribution: [Autom. eng. transl.] Denosumab HTA in the prevention of osteoporosis fractures

Maria Luisa Di Pietro, Rossella Saulle

Research output: Contribution to journalArticlepeer-review

Abstract

[Autom. eng. transl.] As part of the HTA process of Denosumab (Prolia) - a monoclonal antibody capable of inhibiting the activity and development of osteoclasts used in the treatment of osteoporosis - the ethical aspects are analyzed in the light of efficacy, safety and improvement data QoL and economic impact.
Translated title of the contribution[Autom. eng. transl.] Denosumab HTA in the prevention of osteoporosis fractures
Original languageItalian
Pages (from-to)99-104
Number of pages6
JournalItalian Journal of Public Health
Volume2011, vol. 8
Publication statusPublished - 2011

Keywords

  • Denosumab
  • etica
  • hta
  • osteoporosi

Fingerprint Dive into the research topics of '[Autom. eng. transl.] Denosumab HTA in the prevention of osteoporosis fractures'. Together they form a unique fingerprint.

Cite this